FDA issues Flonase, Nasonex letters

Share this article:
The FDA's Division of Drug Marketing, Advertising and Communications has issued untitled letters of violation to Schering-Plough for its Nasonex nasal spray, and to GlaxoSmithKline for its Flonase nasal spray, concerning detail aids used by reps for both brands.

The agency said the sales aids were false and misleading in making superiority claims over each other.

GSK stopped detailing for Flonase in 2006 when the drug went generic. The company is expected to take into account the FDA guidance to develop promotional material for its Flonase follow-on Veramyst.

Schering-Plough spokeswoman Mary-Fran Faraji told The Wall Street Journal the company had already replaced the Nasonex promotional materials. After receiving the FDA letter, the company told its sales reps not to use the old selling aids anymore. The company responded to FDA in writing and is working with the agency to resolve its concerns, she said.  

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...